Post-PhI­II im­plo­sion, Celldex buys on­col­o­gy drug de­vel­op­er Koll­tan in $235M deal

Eight months af­ter watch­ing ex­pec­ta­tions for its can­cer vac­cine Rin­te­ga (rindopepimut) im­plode in a failed Phase III glioblas­toma study, Celldex Ther­a­peu­tics $CLDX is do­ing some …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER